XML 32 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Investments
 12 Months Ended
Apr. 30, 2021
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
Cash Equivalents and Available-for-Sale Marketable Securities
The following table summarizes the Company’s cash equivalents and available-for-sale marketable securities (in thousands):
As of April 30, 2021As of April 30, 2020
Amortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair ValueAmortized CostGross Unrealized GainsGross Unrealized LossesEstimated Fair Value
Cash equivalents:
Money market funds$43,401 $— $— $43,401 $10,260 $— $— $10,260 
Available-for-sale marketable securities:
U.S. treasury securities57,993 5 — 57,998 11,489 11 — 11,500 
Certificates of deposit422,952 32 (6)422,978 28,476 1 — 28,477 
U.S. government agencies securities— — — — 9,995 79 — 10,074 
Commercial paper494,625 64 (13)494,676 94,242 155 — 94,397 
Corporate debt securities2,369 — (1)2,368 68,246 179 — 68,425 
Total cash equivalents and available-for-sale marketable securities$1,021,340 $101 $(20)$1,021,421 $222,708 $425 $— $223,133 
The following table summarizes the Company’s available-for-sale marketable securities by contractual maturity (in thousands):
As of April 30, 2021As of April 30, 2020
Amortized CostFair ValueAmortized CostFair Value
Within one year$977,939 $978,020 $212,449 $212,873 
After one year through five years— — — — 
Total$977,939 $978,020 $212,449 $212,873 
As of April 30, 2021, the Company had 8 investment positions that were in an unrealized loss position. As of April 30, 2020, the Company had 16 investment positions in an unrealized loss position. No investments were other-than-temporary impaired as of April 30, 2021, 2020 or 2019. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company’s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company’s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at April 30, 2021.
Non-Marketable Equity Securities
As of April 30, 2021, the Company had no non-marketable equity securities. As of April 30, 2020, non-marketable equity securities carried at cost of $0.7 million were recorded in long-term investments. The Company recognized an impairment on the non-marketable equity securities of $1.0 million, included in other income (expense), net, on the consolidated statements of operations, during the fiscal year ended April 30, 2020. In November 2020, the Company sold its non-marketable equity security for $0.7 million.